GEN Exclusives

More »

Feature Articles

More »
Jun 15, 2009 (Vol. 29, No. 12)

Protein Engineering Reaches New Frontiers

More Detailed Knowledge of Structure and Function Drives Field Forward Quickly

  • Protein engineering has come a long way since the first monoclonal antibody was humanized in 1988. Novel techniques are improving safety and efficacy, as well as providing alternative delivery routes. In addition, new methodologies are improving the characteristics of current products. Several companies presented their latest efforts at CHI’s “PEGS” meeting held recently in Boston.

    Researchers at the University of Texas, Austin are engineering human therapeutic enzymes for amino-acid depletion therapy in cancer. “We use rational design with high throughput to isolate enzymes or other proteins that have the requisite antibodies for therapeutic applications,” explained George Georgiou, Ph.D., professor, department of biomedical engineering.

    One of the challenges, he said, is finding the mutations that confer a particular function. In addition, it’s a matter of fine-tuning the science because it requires developing a protein that fulfills its ability to function in a particular biochemical activity, remains stable in physiological fluids, doesn’t aggregate, and can be administered to humans without causing an immune response.

    “You have to plan and execute the development program to fulfill all these goals, because not having one of these considerations would render the whole exercise a moot point.”

    Certain cancers require amino acids to grow. Amino-acid depletion therapy has been validated and is effective in acute lymphoblastic leukemia where asparaginase derived from bacteria is used to deplete asparagine. This enzyme is used in conjunction with chemotherapy. The bacterial origin, however, is immunogenic.

    Dr. Georgiou’s lab is developing methods to humanize this enzyme while retaining its properties to deplete asparagine, as well as making a human enzyme to deplete arginine, which has therapeutic effects for liver, melanoma, and prostate cancers.

    Dr. Georgiou’s group uses two approaches to extend the short half-life of enzymes. One is to fuse the protein to the Fc domain in bacteria (faster and less expensive than a mammalian-cell process), and the second method involves conjugation of polymers (polyethylene glycol) onto a protein of interest. “We’re developing more refined ways to do it so the protein stays in circulation for a longer period of time.”

    Prion diseases are well-characterized protein-folding diseases (e.g., Alzheimer’s and Parkinson’s), with early research identifying the conversion of a normal protein, PrP cellular (PrPc), into the pathogenic form, PrP scrapie (PrPsc), mostly in the brain and lymphoreticular systems, as the critical event. This pathologic protein causes loss of neutrophils creating spongiosis and leading to astrocytosis.

    “We started thinking a few years ago that if we could engineer a way to deliver and express an antibody that could block the conversion to PrPsc, that might be a therapeutic strategy to extend life in individuals with prionoses,” stated Howard Federoff, M.D., Ph.D., executive vp for health sciences and executive dean, Georgetown University Medical Center.

    His group engineered a series of single-chain antibodies with one in particular, D18, being the most effective. A mouse model demonstrated that when delivered via a recombinant adeno-associated virus vector, D18 extended the life of mice given the PrPsc antigen by approximately 33%. “This is a proof-of-concept model that showed that this antibody interfered with the conversion process of PrPc to PrPsc. It didn’t prevent death, but it did extend life.”

    Single-chain antibodies are small and can be expressed at high levels and easily engineered because they don’t involve multiple polypeptides interacting with one another. In addition, they can diffuse away from a point source much more readily than a larger antibody. Since they lack the Fc region effector function, they are unlikely to produce Fc-related processes, which translates into fewer adverse events. Dr. Federoff believes that the only potential disadvantage to single-chain antibodies is they have a shorter half-life, requiring higher expression levels.

    Additional studies being conducted by Dr. Federoff’s lab included another set of novel single-chain antibodies his group has identified. One involves antibodies against a protein involved in Parkinson’s disease. Another uses intrabodies (single-chain antibodies that are expressed and retained intercellularly), one of which has recently shown to protect against the production of extracellular amyloid implicated in Alzheimer’s disease. “We are interested in whether these antibodies have the capacity to be translated further and have potential clinical applications.”

  • Enhancing Anticancer Antibodies

    Click Image To Enlarge +
    ImmunoGen’s cytotoxic agents (orange) were developed specifically for attachment to engineered antibodies (purple) for targeted delivery to cancer cells.

    Antibody conjugates have been the main focus of research at ImmunoGen since its origin in 1981. “The goal, even then, was to arm an antibody with a cytotoxic payload in order to make an effective anticancer product,” explained John Lambert, Ph.D., evp and CSO.

    The company’s Tumor-Activated Pro-drug technology (TAP) includes a monoclonal antibody attached to a cell-killing agent via a linker. After trying several molecules, maytansinoids proved most amendable to manipulation. As derivatives of maytansine, DM1 and DM4 are a thousand- to ten-thousand-fold more potent than chemotherapeutics and target tubulin and microtublins, so they only kill dividing cells, Dr. Lamber said. “This contributes to the excellent toxicity profile shown in the clinic.” 

    The company’s approach is to use linker chemistry that reacts with the lysine amino group of the antibody. The linker reaction is controlled by an average of four lysine residues, which maintains the molecule when in circulation, yet enables the cell-killing agent to exert full potency once inside the cancer cell.

    New linkers are being developed that can control what is released inside the cell. “We know maytansine can bind to the tubulin no matter what the linker is. Our new polar linkers resist the efflux mechanisms associated with multidrug resistance much more readily.”

    This efflux process pumps out hydrophobic molecules, so the more hydrophillic the compound, the more it stays inside the cell. “We think our new linkers will enable use to target diseases where multidrug resistance becomes a clinical problem such as colon cancer.”

    Although Dr. Lambert explained that the company is currently focused on applying this technology to cancer, it could be expanded to other diseases such as rheumatoid arthritis, where killing a specific population of cells would have a beneficial effect.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?